Asset Details
Do you wish to reserve the book?
A single centre experience of patients with rare cancers referred for early phase clinical trials
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
A single centre experience of patients with rare cancers referred for early phase clinical trials
Do you wish to request the book?
A single centre experience of patients with rare cancers referred for early phase clinical trials
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
A single centre experience of patients with rare cancers referred for early phase clinical trials
2025
Overview
Background
Cancers affecting < 6/100,000/year are classified as rare, but they account for up to 25% of all cancers and are associated with worse 5-year survival than common cancers. Early-phase clinical trials (EPCTs) may represent a viable treatment option for patients with rare cancers as they have evolved significantly with novel designs and the increasing use of precision medicine.
Methods
A retrospective study of patients with rare cancers referred to a large EPCT team at a UK specialist centre over 5 years (2016–2020) was conducted. Patient demographics, medical and oncological history, genomic variants, EPCT participation, responses and survival outcomes were analysed.
Results
In total, 240 patients with rare cancers were included. The mean age at diagnosis was 51.7 years (range 16–84), 54.2% of the patients were female. The most frequent rare cancers originated from the digestive system (27.1%), female genital tract (20%) and head and neck (H + N) (18.3%). Molecular profiling was offered to 45.5% of the population, median number of gene alterations was 3 per patient (range 1–20) while actionable gene alterations were reported in 60.2% (
n
= 50) of those with identified gene aberrations. Fifty-one patients participated in EPCTs, with 39.2% achieving SD and 11.8% PR. Median PFS for trial participants was three months (95% CI 1.12 – 4.88) while median OS in the trial patients was 16 months (95% CI 9.10 – 22.90) compared to 7 months for non-trial participants (95% CI 5.50 – 8.51). Finally, poor Royal Marsden Hospital (RMH) prognostic score (2–3) was correlated with worse survival when controlling for age and sex (HR 1.714, 95% CI 1.19 – 2.46,
p
= 0.004).
Conclusions
Participation of patients with rare cancers in EPCTs may be associated with a survival benefit and lead to the development of new treatments for these patients. Moreover, expanded use of precision medicine is paramount as it can inform targeted treatment selection in this heterogenous group.
